This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2013
  • /
  • 12
  • /
  • Evidence of Tasgina superiority over Glivec in Ph+...
Drug news

Evidence of Tasgina superiority over Glivec in Ph+CML-Novartis

Read time: 1 mins
Last updated:10th Dec 2013
Published:10th Dec 2013
Source: Pharmawand

Findings from three large, randomized Phase III studies demonstrate the superiority of Tasigna (nilotinib) from Novartis, compared to Glivec (imatinib) at achieving deeper molecular responses across various Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) patient populations, including newly diagnosed patients, patients with residual disease who switched to Tasigna after long-term treatment with Glivec, and patients who failed to respond to frontline Glivec (as defined by 2013 European LeukemiaNet [ELN] guidelines). These results, which were presented in oral sessions at the 55th annual meeting of the American Society of Hematology (ASH) in New Orleans, add to the growing body of evidence confirming the superiority of Tasigna to Glivec at achieving molecular response in Ph+ CML patients.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.